Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update

Silo Pharma, Inc. (NASDAQ:SILO) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 shares, a growth of 58.6% from the March 31st total of 329,449 shares. Based on an average trading volume of 18,681,437 shares, the short-interest ratio is currently 0.0 days. Approximately 3.3% of the shares of the stock are short sold.

Silo Pharma Price Performance

Shares of NASDAQ SILO opened at $0.50 on Monday. Silo Pharma has a one year low of $0.22 and a one year high of $1.17. The firm’s 50 day simple moving average is $0.38 and its two-hundred day simple moving average is $0.41. The stock has a market capitalization of $8.14 million, a P/E ratio of -0.93 and a beta of 0.35.

Silo Pharma (NASDAQ:SILO) last issued its earnings results on Friday, March 27th. The company reported $0.03 earnings per share (EPS) for the quarter. Silo Pharma had a negative net margin of 5,870.83% and a negative return on equity of 83.53%. The firm had revenue of $0.02 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silo Pharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in shares of Silo Pharma by 134.6% in the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after purchasing an additional 53,309 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Silo Pharma in the third quarter worth approximately $74,000. AdvisorShares Investments LLC grew its holdings in shares of Silo Pharma by 98.0% in the third quarter. AdvisorShares Investments LLC now owns 364,878 shares of the company’s stock worth $252,000 after purchasing an additional 180,642 shares during the last quarter. DRW Securities LLC bought a new position in shares of Silo Pharma in the fourth quarter worth approximately $113,000. Finally, Anson Funds Management LP bought a new position in shares of Silo Pharma in the third quarter worth approximately $657,000. Institutional investors own 5.58% of the company’s stock.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.